Sarepta Therapeutics (SRPT)
Add to Watchlists Create an AlertSarepta Therapeutics News
Here's What Investing Giant George Soros Has Been Buying
Fool May 22It can pay off to keep an eye on the most successful investors out there.
Biotech Investing for Beginners
Fool May 223 pointers to help make biotech investing for beginners a little less intimidating.
Sarepta Therapeutics' CEO Presents at 2013 UBS Global Healthcare Conference (Transcript)
Seeking Alpha May 21Sarepta Therapeutics' CEO Presents at 2013 UBS Global Healthcare Conference (Transcript)
2013 FDA Drug Approval Calendar
May 21An updated list of the biotech and drug firms expecting FDA drug approval decisions in 2013.
Requiem for the Bears
May 17If there are any bears left, I hope they aren't trying to short during this bull rampage.
Digging for New Buys
May 17It isn't easy in this market, but two stocks are on my radar this morning.
Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Winner
May 16Sarepta Therapeutics was a winner within the drugs industry, rising $0.58 (1.7%) to $35.51 on light volume
Big Potential, Yet Hurdles Remain for Sarepta Therapeutic (SRPT) - Burrill
Street Insider May 13Sarepta Therapeutics to Present Company Overview at Upcoming Conferences
Marketwired May 10Sarepta Therapeutics , a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the following investor conferences in May. Chris Garabedian, Sarepta's president ...
Biotech Stock Mailbag: Synta, Zogenix, Sarepta, Amarin
May 10Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.
Sarepta Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Seeking Alpha May 9Sarepta Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SRPT | 36.37 | -0.28 | -0.76% | 1.158B |
